Consolidated Results First Quarter Ended June 30, 2013

- 1. Overview
- 2. Financial Position
- 3. Segment Information

July 31, 2013 Ajinomoto Co., Inc.

МЛИОМОТО. 1. (1) Overview of Results

(¥ Billion)

								(+ Dillion)
			AprJune	AprJune	YoY CI	nange	FY2013	Progress
			2013	2012	101 6	lalige	(Forecast)	
			(A)		Amount	%	(B)	A/B
Ne	et sales		242.1	251.0	-8.9	-4%	1,019.0	24%
	Domestic Food P	roducts	77.9	107.1	-29.2	-27%	338.5	23%
	Overseas Food F	Products	71.6	58.0	13.6	24%	303.9	24%
	Bioscience Prod	ucts &	55.1	49.8	5.3	11%	232.8	24%
	Pharmaceuticals		16.8	18.1	-1.4	-8%	52.9	32%
	Other Business		20.7	17.9	2.7	15%	90.9	23%
O	perating income		14.4	19.3	-4.8	-25%	75.0	19%
	Domestic Food P	roducts	5.2	9.0	-3.8	-42%	28.3	19%
	Overseas Food F	Products	6.2	5.2	1.0	19%	23.1	27%
	Bioscience Prod	ucts &	2.5	4.4	-1.8	-42%	19.2	13%
	Fine Chemicals		2.5	4.4	-1.0	-42 /0	19.2	13/0
	Pharmaceuticals	B	0.4	0.7	-0.3	-37%	4.3	10%
	Other Business		0.1	-0.0	0.1	-	0.1	51%
Ordinary income		16.4	20.9	-4.5	-21%	79.0	21%	
Ne	Net income		11.3	10.0	1.3	13%	49.0	23%
E	change rate	JPY/USD	98.78	80.18			90.0	
		JPY/EUR	128.95	102.84			118.0	

Note: Changes due to the introduction of net figure (the method of netting off sales and cost of goods sold and recording the net figure in the accounts) for business tie-ups from FY2013 are as follows:

Scope: Kellogg's products included in the "Seasonings & processed foods" category of Domestic Food Products; the "Edible oils" and "Coffee products" categories of Business Tie-Ups

The former "Business Tie-Ups" segment has been discontinued. "Edible oils" and "Coffee products" have been reclassified as "Edible oils & coffee products" (net figure) in the "Other Business" segment.

Results for FY2012 have been restated to reflect the above changes (for this and all following slides).





1. (2) Comments on Results for the First Three Months of FY2013

Net sales decreased, mainly due to effect of disposal of Calpis shares, etc. despite positive effect of currency translation.

Operating income decreased due to lower income in feed-use amino acids and effect of disposal of Calpis shares, etc.

Net sales / Operating income

(¥ Billion)

	AprJune	AprJune	Change		Full-year	Progress
	2013	2012	Amount	%	Forecast	
Net sales	242.1	251.0	-8.9	-4%	1,019.0	24%
Cost of sales	155.5	149.0	6.5	4%	-	-
SG&A	72.1	82.7	-10.6	-13%	-	-
Operating income	14.4	19.3	-4.8	-25%	75.0	19%

1. Impact of exchange rate (YoY)

Exchange rate for currency translation

Sales ¥22.8 billion; operating income ¥2.5 billion

Exchange rate for trade of main overseas subsidiaries

Sales approx. ¥1.0 billion; operating income approx. -¥0.5 billion

2. Impact of raw material & fuel prices (YoY) Fermentation raw materials and fuel prices approx. -¥0.6 billion

Domestic food products raw materials approx. -¥0.7 billion

3. Cost reductions (YoY)

Domestic food products approx. ¥0.7 billion

Pharmaceuticals approx. ¥0.7 billion

(-: Cost increase)





JINOMOTO. 1. (3) Comments on Results for the First Three Months of FY2013

Ordinary income

(¥ Billion)

	AprJune	AprJune	Change		Full-year	Progress
	2013	2012	Amount	%	Forecast	
Non-operating income (net)	1.9	1.6	0.4	23%	-	-
Ordinary income	16.4	20.9	-4.5	-21%	79.0	21%

* None


Net income

	AprJune	AprJune	e Change F		Full-year	Progress
	2013	2012	Amount	%	Forecast	
Extraordinary gains	1.3	0.8	0.5	62%	-	-
Extraordinary losses	1.1	3.0	-1.9	-64%	-	-
Income taxes etc.	3.4	7.0	-3.6	-51%	-	-
Minority interests	1.9	1.7	0.2	12%	-	-
Net income	11.3	10.0	1.3	13%	49.0	23%

- * Insurance income ¥1.2 billion (¥1.2 billion increase)
- * Loss on devaluation of securities ¥0.0 billion (¥2.4 billion decrease)
- * Loss on liquidation of subsidiaries ¥0.6 billion (¥0.6 billion increase)



AJINOMOTO. 2. Financial Position



Current assets 586.1 Prixed assets 691.7 Incl. Minority 56.4 interests

¥5.0 billion increase in total assets from March 31, 2013

- * Increase in goodwill because of acquisition of all the stock of Althea Technologies, Inc.
- * Increase in yen values of the balance sheets of overseas subsidiaries after currency translation.

Cash Flow

(¥ Billion)

	June 2013	June 2012	Change
1. CF from operating activities	-0.3	14.1	-14.4
2. CF from investing activities	-28.3	-16.2	-12.1
3. CF from financing activities	-11.4	-30.8	19.4
4. Cash and cash equivalents	144.5	107.4	37.1
FCF(1+2)	-28.6	-2.2	-26.5

*Cash out is shown with -.

Capital expenditures	13.5	16.4	-2.9
Depreciation and amortization	11.3	10.4	0.9

Interest-bearing Debt


(¥ Billion)

<Reference>

June 2013	June 2012	Change	June 2011
145.4	132.9	12.5	136.9



JINOMOTO. 3. (1) Change by Business Segment



JINOMOTO. 3. (2) Domestic Food Products

				(¥ Billion)
	AprJune 2013	Full-year Forecast	Progress	AprJune 2012	Change
Net sales	77.9	338.5	23%	107.1	-29.2
Seasonings & processed foods	48.9	-	-	51.4	-2.5
Frozen foods	29.0	-	-	28.2	0.8
Beverages ("Calpis")	0.0	0.0	-	27.6	-27.6
Operating income	5.2	28.3	19%	9.0	-3.8
Seasonings & processed foods	5.8	-	-	7.5	-1.7
Frozen foods	1.2	-	-	2.4	-1.2
Beverages ("Calpis")	0.0	0.0	-	1.9	-1.9
Shared companywide expenses	-1.7	-7.6	23%	-2.8	1.0

^{*1} Decrease in sales due to end of sales of beverage gifts resulting from disposal of Calpis shares, etc., despite firm sales of home-use products.



^{*2} Increase in sales because of strong sales overseas, mainly in North America, despite flat sales in Japan.

^{*3} Decrease due to disposal of Calpis shares in October 2012.

^{*4} Decrease in income due to effect of disposal of shares of Calpis, whose sales included beverage gifts, impact of higher raw material prices and higher selling expenses, etc.

JINOMOTO₈ 3. (3) Overseas Food Products

(¥ Billion)

		AprJune 2013	Full-year Forecast	Progress	AprJune 2012	Change
Ne	t sales	71.6	303.9	24%	58.0	13.6
	Consumer foods	58.4	254.5	23%	46.9	11.5
	Umami seasonings for processed food mfrs.	13.2	49.4	27%	11.1	2.1
Op	erating income	6.2	23.1	27%	5.2	1.0
	Shared companywide expenses	-2.2	-9.4	24%	-2.1	-0.2

[Effect of currency translation]: Net sales +¥13.7 billion; operating income +¥1.9 billion

Reference: Consumer foods +¥1.9 billion; umami seasonings for processed food mfrs. -¥0.8 billion



^{*1} Increase in sales because of positive effect of currency translation and higher sales volume, mainly of flavor seasonings, etc.

^{*2} Increase in sales because of positive effect of currency translation and higher overseas sales volume of MSG and nucleotides, etc.

^{*3} Increase in income as positive effect of currency translation, etc., offset negative impact of lower unit price of umami seasonings for processed food mfrs.

JINOMOTO. 3. (4) Bioscience Products & Fine Chemicals

(¥ Billion)

		AprJune 2013	Full-year Forecast	Progress	AprJune 2012	Change	
Ne	t sales	55.1	232.8	24%	49.8	5.3	
	Feed-use amino acids	23.7	108.5	22%	23.3	0.4	*1
	Amino acids	19.1	-	-	15.4	3.6	*2
	Specialty chemicals	11.1	-	-	10.0	1.1	*3
Ор	erating income	2.5	19.2	13%	4.4	-1.8	*4
	Feed-use amino acids	0.8	13.8	6%	3.8	-3.0	
	Amino acids	1.2	-	-	1.0	0.1	
	Specialty chemicals	2.5	-	-	1.8	0.7	
	Shared companywide expenses	-1.6	-6.4	25%	-1.5	-0.1	

[Effect of currency translation]: Net sales +¥7.7 billion; operating income +¥0.4 billion

- *1 Increase in sales from positive effect of currency translation, despite decreases in Lysine unit price and sales volume.
- *2 Amino acids for pharmaceuticals and foods +¥2.2 billion; pharmaceutical custom manufacturing (formerly pharmaceutical fine chemicals) +¥0.9 billion; sweeteners +¥0.6 billion.
- *3 Sales of both cosmetics and cosmetic ingredients and chemicals increased.
- *4 Decrease in income because higher income of specialty chemicals and amino acids for pharmaceuticals and foods, etc., did not offset lower income of feed-use amino acids and pharmaceutical custom manufacturing.

 Reference: Within amino acids, amino acids for pharmaceuticals and foods +¥0.6 billion; pharmaceutical custom manufacturing -¥0.7 billion; sweeteners +¥0.2 billion

Note: Pharmaceutical custom manufacturing (formerly pharmaceutical fine chemicals): A business that provides pharmaceutical intermediate and bulk drug manufacturing and development services to pharmaceutical manufacturers. From this first quarter, the results of Ajinomoto Althea, Inc. are reflected in this business.



JINOMOTO. 3. (5) Pharmaceuticals

(¥ Billion)

		AprJune 2013	Full-year Forecast	Progress	AprJune 2012	Change	
Ne	t sales	16.8	52.9	32%	18.1	-1.4	*1
Op	erating income	0.4	4.3	10%	0.7	-0.3	*2
	Shared companywide expenses	-0.5	-1.5	31%	-0.5	0.1	

*1 Increase in sales of self-distributed products with the contribution of *MARZULENE* in-licensing and new product *MOVIPREP*. Sales of products sold through business tie-ups decreased due to growth of competing products, including generics.

Sales based on AJINOMOTO PHARMACEUTICALS CO., LTD. estimated drug prices (% = YoY change from previous year):

LIVACT	¥3.8 billion	(-4%)	ATELEC	¥3.8 billion	(-3%)
ELENTAL	¥1.9 billion	(-1%)	ACTONEL	¥2.6 billion	(-16%)
CARBOSTAR	¥1.6 billion	(-1%)	FASTIC	¥0.5 billion	(-30%)
SOLITA-T	¥1.0 billion	(-1%)			

*2 Decrease in income due to lower sales of products sold through business tie-ups despite higher sales of self-distributed products and cost reductions, etc.



JINOMOTO. 3. (6) Other Business

Other Business		AprJune 2013	Full-year Forecast	Progress	AprJune 2012	Change	
Ne	t sales	20.7	90.9	23%	17.9	2.7	*1
	Edible oils & Coffee products	0.5	-	-	0.5	0.0	
Operating income		0.1	0.1	39%	-0.0	0.1	*2
	Edible oils & Coffee products	0.5	-	-	0.5	0.0	
	Shared companywide expenses	-0.7	-3.2	23%	-0.7	0.0	

^{*1} Increase in sales due to impact of change of segment for medical foods (Pharmaceuticals → Other Business), and logistics business etc.

^{*2} Increase in income due to higher income in wellness business.



3. (7) Net Sales by Business & Geographical Area

Upper row: Apr.-June 2013; lower row: Apr.-June 2012.

Figures in parentheses represent YoY change.

	Japan	Asia	Americas	Europe	Total		
Domestic Food	73.5 (-29.8)	1.4 (-0.1)	2.7 (0.8)	0.4 (0.0)	77.9 (-29.2)		
Products	103.3	1.5	1.9	0.4	107.1		
Overseas Food	2.2 (-0.2)	49.0 (10.1)	13.1 (2.5)	7.2 (1.2)	71.6 (13.6)		
Products	2.4	38.9	10.7	6.0	58.0		
Bioscience Products	15.1 (-0.1)	4.9 (1.0)	17.4 (2.4)	17.7 (2.0)	55.1 (5.3)		
& Fine Chemicals	15.2	3.8	15.0	15.7	49.8		
Pharmaceuticals	16.8 (-1.4)				16.8 (-1.4)		
	18.1				18.1		
Other Business	18.2 (2.3)	2.4 (0.4)	0.0 (0.0)		20.7 (2.7)		
Other Business	15.9	2.0	0.0		17.9		
Total	125.8 (-29.2)	57.7 (11.4)	33.3 (5.7)	25.3 (3.2)	242.1 (-8.9)		
i Otai	155.1	46.2	27.6	22.1	251.0		





3. (8) Operating Income by Business & Geographical Area

Upper row: Apr.-June 2013; lower row: Apr.-June 2012 Figures in parentheses represent YoY change.

	Jap	Japan Asia		Americas		Europe		Other *		Total		
Domestic Food	6.2	(-5.0)	0.5	(0.2)	0.3	(0.1)	0.1	(-0.0)	-1.8	(1.0)	5.2	(-3.8)
Products	11.2		0.3		0.2		0.1		-2.8		9.0	
Overseas Food	-0.5	(0.4)	7.6	(1.0)	1.6	(0.1)	0.0	(-0.3)	-2.5	(-0.1)	6.2	(1.0)
Products	-0.9		6.6		1.5		0.3		-2.4		5.2	
Bioscience Products & Fine	3.3	(1.5)	0.4	(-0.6)	-0.0	(-1.5)	1.2	(-0.4)	-2.4	(-0.8)	2.5	(-1.8)
Chemicals	1.9		1.0		1.5		1.6		-1.6		4.4	
Pharmaceuticals	0.9	(-0.3)							-0.5	(0.1)	0.4	(-0.3)
	1.2								-0.5		0.7	
Other Business	0.5	(-0.1)	0.4	0.3	0.0	(-0.0)	-0.0	(0.0)	-0.9	(-0.1)	0.1	(0.1)
Other Business	0.6		0.1		0.0		-0.0		-0.7		-0.0	
Shared companywide*	-4.0	(0.7)	-2.2	(-0.4)	-1.1	(-0.2)	-0.8	(-0.1)	-8.0	(-0.0)		
expenses, etc.	-4.7		-1.7		-0.9		-0.7		-8.0			
Total	6.5	(-2.9)	6.7	(0.4)	0.8	(-1.6)	0.5	(-0.8)			14.4	(-4.8)
Total	9.4	, ,	6.3	, ,	2.3		1.3	. ,			19.3	, ,



^{*} Other includes shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



3. (9) Comments on Operating Income by Business & Geographical Area

Apr.-June FY2013 Change Compared with Same Period of Previous Year

1. Overseas Food Products

(¥ Billion)

[YoY change]
Japan +¥0.4; Asia +¥1.0; Americas +¥0.1; Europe -¥0.3; Other* -¥0.1; Total +¥1.0

Asia: Increase due to positive effect of currency translation and higher sales of consumer foods products, etc.

2. Bioscience Products & Fine Chemicals

[YoY change] (¥ Billion)

Japan +¥1.5; Asia -¥0.6; Americas -¥1.5; Europe -¥0.4; Other* -¥0.8; Total -¥1.8


- (1) Japan: Increase due to specialty chemicals and sweeteners, etc.
- (2) Americas: Decrease due to feed-use amino acids, etc.



^{*} Shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



(Reference) Feed-Use Lysine Market Price and CBOT Spread* Trend





- ➤ Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- ➤ Unaudited figures are included in these materials for reference.
- ➤ Amounts presented in these materials are rounded off.